---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-058584"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:49:48.469074+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics Q4/FY2023: VOWST net sales $10.4M Q4, $19.6M YTD; net loss narrows to $113.7M

## Summary
- Net loss of $113.7M for FY2023 versus $250.2M prior year; Q4 net loss $41.2M vs $68.8M.
- VOWST net sales $10.4M in Q4, $19.6M since June launch; 2,833 enrollment forms, 2,015 new patient starts.
- Restructuring expected to save $75-85M annually; cash and equivalents $128.0M at year-end.
- SER-155 Phase 1b Cohort 2 data readout anticipated in Q3 2024; Fast Track designation awarded.
- Appointed Marella Thorell as EVP/CFO following retirement of David Arkowitz.

## SEC filing metadata
- accession: 0001193125-24-058584
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/0001193125-24-058584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/d806486d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-058584
- JSON: https://secwatch.observer/filing/0001193125-24-058584.json
- Plain text: https://secwatch.observer/filing/0001193125-24-058584.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: revenue $10.4 million, net income $41.2 million.
  - Period: quarter and year ended December 31, 2023
  - Revenue: $10.4 million
  - Net income: $41.2 million
  - Result: reported results
  source text: Seres reported a net loss of $41.2 million for the fourth quarter of 2023, as compared to a net loss of $68.8 million for the same period in 2022. Net sales of VOWST for the fourth quarter and full year 2023, were $10.4 million and $19.6 million, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/0001193125-24-058584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.